Hjem › Burkitts lymfom › Maryland › Baltimore
Kliniske studier for Burkitts lymfom i Baltimore, MD
8 studier for Burkitts lymfom søker deltakere på steder i og rundt Baltimore (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
RekruttererFase 2
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
RekruttererFase 3
- University of Maryland/Greenebaum Cancer Center, Baltimore
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
RekruttererFase 2
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
RekruttererFase 3
- Johns Hopkins Asthma & Allergy Center, Baltimore
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RekruttererFase 1
- University of Maryland, Baltimore
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
RekruttererFase 2
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
RekruttererFase 3
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
RekruttererFase 1
- University of Maryland, Baltimore
Burkitts lymfom-studier i andre byer
- Houston, TX21 studier
- Milwaukee, WI16 studier
- Philadelphia, PA16 studier
- New York City, NY14 studier
- Chicago, IL14 studier
- Cincinnati, OH12 studier
- Atlanta, GA12 studier
- Seattle, WA11 studier
- Durham, NC10 studier
- Boston, MA10 studier
- Los Angeles, CA10 studier
- Aurora, CO10 studier
Andre studier i Baltimore
- Ikke-småcellet lungekreft60 studier
- Brystkreft47 studier
- Prostatakreft43 studier
- Lungekreft40 studier
- Kreft (alle typer)37 studier
- Kolorektal kreft31 studier
- Pankreaskreft31 studier
- Metastatisk kreft28 studier
- Fedme25 studier
- Hjertesvikt24 studier
- Blærekreft24 studier
- Slag22 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.